Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $6.8200 (-0.44%) ($6.6800 - $6.9700) on Tue. May. 14, 2019. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 5.27% (three month average) | RSI | 32 | Latest Price | $6.8200(-0.44%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX declines -3% a day on average for past five trading days. | Weekly Trend | TGTX declines -3.4% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) XBI(65%) ARKG(58%) IBB(58%) ARKK(57%) IWO(57%) | Factors Impacting TGTX price | TGTX will decline at least -2.635% in a week (0% probabilities). VXX(-38%) TLT(-9%) VIXM(-7%) UUP(-6%) IFRA(-6%) | | | | | Relative Volatility | | | | Market Trend Strength | -2.635% (StdDev 5.27%) | Hourly BBV | 0 () | Intraday Trend | -1.9% | | | |
|
1 - 5 Day Possible Target | $-1.96(-128.74%) | Resistance Level | $7.88 | 5 Day Moving Average | $7.5(-9.07%) | 10 Day Moving Average | $7.75(-12%) | 20 Day Moving Average | $7.88(-13.45%) | To recent high | -19.6% | To recent low | 31.4% | Market Cap | $864m | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |